Aerie Pharmaceuticals Inc (NASDAQ:AERI) has been given a consensus recommendation of “Buy” by the sixteen research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $70.17.
AERI has been the topic of a number of recent analyst reports. Guggenheim initiated coverage on Aerie Pharmaceuticals in a report on Monday, October 23rd. They set a “buy” rating and a $80.00 price target on the stock. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Mizuho reissued a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, November 3rd. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $62.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, October 11th.
Aerie Pharmaceuticals (AERI) traded down $0.80 during trading hours on Tuesday, reaching $57.80. The company’s stock had a trading volume of 331,092 shares, compared to its average volume of 270,244. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $2,120.00, a PE ratio of -17.25 and a beta of 1.11. Aerie Pharmaceuticals has a twelve month low of $38.14 and a twelve month high of $66.60.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.89) EPS for the quarter. research analysts forecast that Aerie Pharmaceuticals will post -3.94 EPS for the current year.
Several hedge funds have recently modified their holdings of AERI. Ameritas Investment Partners Inc. grew its position in Aerie Pharmaceuticals by 11.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after acquiring an additional 275 shares in the last quarter. Legal & General Group Plc grew its position in Aerie Pharmaceuticals by 7.4% in the second quarter. Legal & General Group Plc now owns 7,534 shares of the company’s stock worth $396,000 after acquiring an additional 519 shares in the last quarter. Bamco Inc. NY grew its position in Aerie Pharmaceuticals by 13.4% in the second quarter. Bamco Inc. NY now owns 5,511 shares of the company’s stock worth $290,000 after acquiring an additional 653 shares in the last quarter. Chartwell Investment Partners LLC grew its position in Aerie Pharmaceuticals by 3.2% in the third quarter. Chartwell Investment Partners LLC now owns 25,591 shares of the company’s stock worth $1,243,000 after acquiring an additional 791 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Aerie Pharmaceuticals by 5.5% in the second quarter. The Manufacturers Life Insurance Company now owns 23,501 shares of the company’s stock worth $1,235,000 after acquiring an additional 1,235 shares in the last quarter.
COPYRIGHT VIOLATION WARNING: “Aerie Pharmaceuticals Inc (AERI) Given Average Rating of “Buy” by Analysts” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/16/aerie-pharmaceuticals-inc-aeri-given-average-rating-of-buy-by-analysts.html.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.